Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Marien Hospital Dusseldorf; Klinik fur Onkologie und Hamatologie, Palliativmedizin

Wednesday, October 23, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article provides an overview of Marien Hospital Dusseldorf, focusing on its oncology and hematology departments. It details the hospital's collaborations, patient studies, and pipeline of treatments, including Emavusertib and Fimepinostat. Additionally, it highlights the hospital's commitment to patient care and research initiatives.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 40 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What services does Marien Hospital Dusseldorf offer?

Marien Hospital Dusseldorf specializes in oncology and hematology, providing comprehensive patient care.

What studies are currently sponsored by Marien Hospital?

The hospital sponsors studies including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What treatments are included in the hospital's pipeline?

The pipeline includes treatments like Emavusertib (CA-4948) and Fimepinostat.

How does Marien Hospital support patient care?

The hospital emphasizes patient care through compassionate use policies and ongoing research.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Marien Hospital oncology hematology clinical studies
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →